Get the Stockscreener App
528.96
1.10%
5.73
Pre-market:
529.00
0.04
+0.01%
Overview
News
Price History
Option Chain
Financials
Why TMO Down?
Discussions
Forecast
Stock Split
Dividend History
Thermo Fisher Scientific Inc stock is traded at $528.96, with a volume of 2.09M.
It is up +1.10% in the last 24 hours and down -11.51% over the past month.
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of mid-2024 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (22%); and lab products and services, which includes CRO services (54%).
See More
Previous Close:
$523.23
Open:
$528.26
24h Volume:
2.09M
Relative Volume:
1.10
Market Cap:
$199.56B
Revenue:
$42.88B
Net Income/Loss:
$6.34B
P/E Ratio:
32.00
EPS:
16.53
Net Cash Flow:
$7.27B
1W Performance:
-0.67%
1M Performance:
-11.51%
6M Performance:
-14.00%
1Y Performance:
-7.23%
1-Day Range:
$520.58
$530.05
1-Week Range:
$519.13
$543.85
52-Week Range:
$493.30
$627.88
Thermo Fisher Scientific Inc Stock (TMO) Company Profile
Name
Thermo Fisher Scientific Inc
Sector
Industry
Phone
(781) 622-1000
Address
168 THIRD AVENUE, WALTHAM, MA
Compare TMO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TMO
Thermo Fisher Scientific Inc
|
528.96 | 199.56B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
207.76 | 148.49B | 23.88B | 3.90B | 5.30B | 5.28 |
|
A
Agilent Technologies Inc
|
127.92 | 36.78B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IDXX
Idexx Laboratories Inc
|
437.11 | 35.55B | 3.90B | 887.87M | 798.08M | 10.67 |
|
IQV
Iqvia Holdings Inc
|
188.80 | 33.25B | 15.41B | 1.37B | 2.11B | 7.50 |
Thermo Fisher Scientific Inc Stock (TMO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-25 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Dec-23-24 | Initiated | Scotiabank | Sector Perform |
| Oct-14-24 | Initiated | Redburn Atlantic | Buy |
| Oct-01-24 | Initiated | Stephens | Overweight |
| Aug-28-24 | Initiated | Wells Fargo | Overweight |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Mar-18-24 | Resumed | Citigroup | Neutral |
| Jan-24-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Jan-08-24 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Dec-18-23 | Initiated | HSBC Securities | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Oct-26-23 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Oct-25-23 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Sep-06-23 | Resumed | Citigroup | Buy |
| Jul-19-23 | Initiated | Raymond James | Outperform |
| Jul-19-23 | Reiterated | Robert W. Baird | Outperform |
| Jul-13-23 | Upgrade | Credit Suisse | Neutral → Outperform |
| Apr-04-23 | Reiterated | Barclays | Overweight |
| Dec-14-22 | Initiated | Deutsche Bank | Buy |
| Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
| Oct-27-22 | Downgrade | The Benchmark Company | Buy → Hold |
| Aug-25-22 | Initiated | Credit Suisse | Neutral |
| Apr-25-22 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| Jan-26-22 | Resumed | Barclays | Overweight |
| Oct-20-21 | Upgrade | Citigroup | Neutral → Buy |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Jul-16-21 | Initiated | The Benchmark Company | Buy |
| Mar-18-21 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Mar-03-21 | Initiated | Barclays | Overweight |
| Jan-08-21 | Upgrade | Credit Suisse | Neutral → Outperform |
| Dec-16-20 | Downgrade | Citigroup | Buy → Neutral |
| Dec-02-20 | Initiated | Goldman | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Sep-30-20 | Initiated | Atlantic Equities | Overweight |
| Sep-14-20 | Initiated | Morgan Stanley | Overweight |
| Aug-20-20 | Resumed | JP Morgan | Overweight |
| Jul-15-20 | Upgrade | Cleveland Research | Neutral → Buy |
| Jul-07-20 | Reiterated | Needham | Buy |
| Apr-23-20 | Reiterated | Needham | Buy |
| Jan-31-20 | Reiterated | Needham | Buy |
| Jan-22-20 | Initiated | Credit Suisse | Neutral |
| Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Nov-15-19 | Initiated | Stifel | Buy |
| Jul-25-19 | Reiterated | Needham | Buy |
| Jul-16-19 | Downgrade | Needham | Strong Buy → Buy |
| May-30-19 | Initiated | Wolfe Research | Outperform |
| May-23-19 | Reiterated | Needham | Strong Buy |
| Apr-22-19 | Reiterated | Needham | Strong Buy |
| Apr-16-19 | Reiterated | BofA/Merrill | Buy |
View All
Thermo Fisher Scientific Inc Stock (TMO) Latest News
Thermo Fisher Scientific to Acquire Purification and Filtration Business - MedTech Intelligence
Thermo Fisher Expands Horizons with Bold $4.1 Billion Acquisition - Clinique Bio
Thermo Fisher (TMO): Among the Best Affordable Dividend Stocks to Buy According to Hedge Funds - Insider Monkey
Global Blood Bank Market to Register Immense Growth at a CAGR of ~7% by 2032 | DelveInsight - GlobeNewswire Inc.
Thermo Fisher Scientific Agreed to Acquire Solventum’s Purification and Filtration Business - Genetic Engineering & Biotechnology News
Microplastic Detection Market Report 2025, with Key Player Profiles for Thermo Fisher Scientific, Agilent Technologies, Bruker, JEOL and PerkinElmerResearchAndMarkets.com | FinancialContent Business Page - Financial Content
Rx Rundown: Thermo Fisher Scientific, the CDC, Eli Lilly and more - MM+M Online
Biotechnology company Thermo Fisher Scientific buys Solventum’s filtration and purification business for $4.1 billion - BioProcess Insider
Cell Culture Market Is Booming So Rapidly: Cell Culture Company, LLC, Thermo Fisher Scientific Inc. - openPR
Custom Antibody Service Market Growth in Future Scope 2025-2032 - openPR
Thermo Fisher Scientific, Inc. to Host Earnings Call - ACCESS Newswire
Thermo Fisher Scientific Inc. stock falls Thursday, underperforms market - MarketWatch
Thermo Fisher Scientific: $4.1 Billion Deal For Solventum’s Purification And Filtration Business - Pulse 2.0
Thermo Fisher Scientific (NYSE:TMO) Launches CorEvitas Registry To Advance Lupus Research And Treatment - Simply Wall St
Thermo Fisher tests limits of Swiss market with Sfr1.425bn deal - GlobalCapital
TMO April 11th Options Begin Trading - Nasdaq
Spatial Imaging System | Thermo Fisher Scientific Inc. | Products - Photonics.com
Recall issued on Thermo Fisher Scientific CryoMed Controlled Rate Freezer - NTV News
Raman Spectroscopy Market to Witness Remarkable Growth with Thermo Fisher Scientific Inc., Merck KGaA - openPR
Immune Cell Engineering Market Is Booming Worldwide | Thermo Fisher Scientific Inc., Merck KGaA - openPR
Thermo Fisher Acquires Solventum Filtration Arm in $4.1B Deal - Asia Business Outlook
Sample Preparation Market Key Players AnalysisMerck KgaA, - openPR
Thermo Fisher strikes $4.1bn deal for Solventum’s purification and filtration unit - MSN
Thermo Fisher’s $4.1 Billion Acquisition of Purification and Filtration Business from Solventum - Global Legal Chronicle
Thermo Fisher spending $4.1B for purification and filtration business - 69News WFMZ-TV
Deals of the day-Mergers and acquisitions -February 26, 2025 at 09:55 am EST - Marketscreener.com
Thermo Fisher to Buy Solventum Purification, Filtration Business for $4.1 Billion - MSN
Thermo Fisher Scientific Launches CorEvitas Clinical Registry and Biorepository in Systemic Lupus Erythematosus - The Bakersfield Californian
Deals of the day-Mergers and acquisitions -February 26, 2025 at 05:50 am EST - Marketscreener.com
Layoff Tracker: Lava, Ryvu Cutting 30% of Their Workforces - BioSpace
3D Printing Photopolymer Market Key Players AnalysisBomar, - openPR
Solventum Stock Jumps After Thermo Fisher Strikes Deal for Filtration Business - The Wall Street Journal
Bitcoin slides under $90,000, erasing some of the gains made under Trump - The Boston Globe
Solventum sells $4.1B purification unit to Thermo Fisher - BioWorld Online
Thermo Fisher inks $4 billion deal to buy former 3M filtration business - The Boston Globe
Thermo Fisher's SWOT analysis: stock outlook amid acquisition, china growth - Investing.com India
Thermo Fisher’s SWOT analysis: stock outlook amid acquisition, china growth - Investing.com
Thermo Fisher's SWOT analysis: stock outlook amid acquisition, china growth By Investing.com - Investing.com UK
Solventum’s $4.1 Billion Sale of Purification and Filtration Business to Thermo Fisher - Cleary Gottlieb
Thermo Fisher to Buy Solventum Purification, Filtration Business for $4.1 Billion -February 25, 2025 at 03:22 pm EST - Marketscreener.com
Solventum Corp. sells unit to Thermo Fisher for $4.1B - The Business Journals
WilmerHale, Cleary Steer $4.1B Thermo Fisher-Solventum Deal - Law360
Thermo Fisher to acquire Solventum’s Purification & Filtration business for US$4.1bn - Filtration + Separation
Solventum to Sell Purification Business for $4.1B - Twin Cities Business Magazine
Solventum Stock Jumps After $4.1B Deal With Thermo Fisher - Investopedia
Solventum sells purification business for $4.1B to pay down debt - Star Tribune
Thermo Fisher makes a $4B acquisition - NBC Boston
Thermo Fisher buys Solventum business unit and its 2,500 employees for $4B - The Business Journals
Thermo Fisher Beefs Up in Bioprocessing With $4B Acquisition of Solventum Biz Segment - MedCity News
12 High Growth Low Dividend Stocks To Invest In - Insider Monkey
Thermo Fisher buys biologics purification business from Solventum for $4.1B - Endpoints News
Thermo Fisher Scientific Inc Stock (TMO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.00%
0.89%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):